27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Fireside chat details: | |
Date: | Tuesday, April 13, 2021 |
Time: | 2:30 – 3:20 p.m. Eastern Time (ET) |
Panel title: | COVID-19 Vaccines – Staying Ahead of the Curve |
Novavax participant: | Vivek Shinde, M.D., M.P.H., Vice President, Clinical Development |
This event is open to Goldman Sachs clients. |
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
About Novavax
Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Jennifer Porcelli | 646-378-2962
jporcelli@soleburytrout.com
Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
media@novavax.com
SOURCE Novavax, Inc.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.